Economy & Markets
Novo Nordisk CEO sees ‘long runway’ for weight-loss drugs as obesity grips America
Novo Nordisk CEO argues weight loss drugs could slash healthcare costs and boost productivity as GLP-1 adoption remains in its early innings.
Read more at FOX BIZ ›
Read the full story at
FOX BIZ
The Gadsden Report aggregates and summarises headlines. The reporting above belongs to FOX BIZ, and the link opens their page. This page exists so readers can find, share, and discuss the story here.